|
Aug 2
|
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
|
|
Aug 2
|
Q2 2024 Ionis Pharmaceuticals Inc Earnings Call
|
|
Jul 30
|
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
|
Jul 30
|
FDA grants priority review for Novartis’ leukaemia treatment
|
|
Jul 25
|
Dren Bio and Novartis link on bispecific antibodies for cancer
|
|
Jul 24
|
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
|
|
Jul 24
|
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
|
|
Jun 11
|
Is Novartis AG (NYSE:NVS) Investors’ Favorite International Dividend Stock?
|
|
Mar 25
|
30 Countries with Highest Proportion of Older Adults
|
|
Mar 24
|
1 Magnificent Dividend Stock to Buy and Hold
|
|
Mar 22
|
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Mar 19
|
Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know
|
|
Mar 18
|
Novartis (NVS) Stock Dips While Market Gains: Key Facts
|
|
Feb 14
|
30 Countries with Highest Standard of Living Ranked by GDP (PPP) Per Capita
|
|
Feb 14
|
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
|
|
Feb 10
|
30 Most Valuable Drug Companies in 2024
|
|
Feb 9
|
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
|
|
Feb 9
|
Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals
|
|
Feb 9
|
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO
|
|
Jan 19
|
Bill Gates, will.i.am, top execs on AI: Davos best moments
|